Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
July 27, 2023 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., and DEVENS, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur...
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
July 26, 2023 07:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast...
Editas Medicine Reports Inducement Grant to New Chief Scientific Officer
July 25, 2023 08:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the grant of an inducement award to the Company’s...
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
July 24, 2023 07:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the...
Editas Medicine Announces Pricing of Offering of Common Stock
June 14, 2023 22:06 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of...
Editas Medicine Announces Offering of Common Stock
June 14, 2023 16:05 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of...
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
June 09, 2023 03:00 ET
|
Editas Medicine, Inc.
EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant First two RUBY patients...
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
June 06, 2023 08:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on Monday, June...
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
May 18, 2023 16:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s...
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
May 16, 2023 16:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Erick J. Lucera as Executive...